These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24301867)

  • 1. Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain.
    Rungta RL; Choi HB; Lin PJ; Ko RW; Ashby D; Nair J; Manoharan M; Cullis PR; Macvicar BA
    Mol Ther Nucleic Acids; 2013 Dec; 2(12):e136. PubMed ID: 24301867
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kawase W; Kurotaki D; Suzuki Y; Ishihara H; Ban T; Sato GR; Ichikawa J; Yanai H; Taniguchi T; Tsukahara K; Tamura T
    Mol Ther Nucleic Acids; 2021 Sep; 25():708-715. PubMed ID: 34589288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
    Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
    ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material.
    Tanaka H; Takata N; Sakurai Y; Yoshida T; Inoue T; Tamagawa S; Nakai Y; Tange K; Yoshioka H; Maeki M; Tokeshi M; Akita H
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33924589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
    Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
    Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
    Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
    Suzuki Y; Ishihara H
    Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids.
    Ehexige E; Ganbold T; Yu X; Han S; Baigude H
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31546908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
    Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
    Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation.
    Paunovska K; Sago CD; Monaco CM; Hudson WH; Castro MG; Rudoltz TG; Kalathoor S; Vanover DA; Santangelo PJ; Ahmed R; Bryksin AV; Dahlman JE
    Nano Lett; 2018 Mar; 18(3):2148-2157. PubMed ID: 29489381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
    Zhang J; Haas RM; Leone AM
    Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
    Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
    J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy.
    Francia V; Schiffelers RM; Cullis PR; Witzigmann D
    Bioconjug Chem; 2020 Sep; 31(9):2046-2059. PubMed ID: 32786370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.